Literature DB >> 20697031

Plasma ß-amyloid and cognitive decline.

Stephanie A Cosentino1, Yaakov Stern, Elisaveta Sokolov, Nikolaos Scarmeas, Jennifer J Manly, Ming Xin Tang, Nicole Schupf, Richard P Mayeux.   

Abstract

OBJECTIVES: To determine if plasma β-amyloid (Aβ) levels (1) can be linked to specific cognitive changes that constitute conversion to Alzheimer disease (AD) and (2) correspond to cognitive change independent of dementia.
DESIGN: Longitudinal study including 3 visits during approximately 4¹/₂ years (2000-2006).
SETTING: Northern Manhattan community. PARTICIPANTS: Eight hundred eighty individuals from a population-based and ethnically diverse sample who had 2 plasma Aβ measurements and were dementia free at the time of the first Aβ sample; 481 remained cognitively healthy, 329 were cognitively or functionally impaired but not demented at any point, and 70 developed AD. MAIN OUTCOME MEASURES: General estimating equations tested the association between plasma Aβ (baseline and change in values) and cognitive change (composite score and memory, language, and visuospatial indices).
RESULTS: High baseline plasma Aβ42 (P = .01) and Aβ40 (P = .01) and decreasing/relatively stable Aβ42 (P = .01) values were associated with faster decline in multiple cognitive domains. In those who remained cognitively healthy, high baseline plasma Aβ42 (P = .01) and decreasing/relatively stable plasma Aβ42 (P = .01) was associated with faster cognitive decline, primarily in memory.
CONCLUSIONS: The association between plasma Aβ and multiple aspects of cognition more clearly specifies the previously documented downward trajectory of plasma Aβ with AD onset. The predominant association with memory seen only in healthy elderly individuals also suggests that plasma Aβ is linked with even earlier neurologic changes that may or may not culminate in dementia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697031      PMCID: PMC3006003          DOI: 10.1001/archneurol.2010.189

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  24 in total

1.  Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Authors:  P D Mehta; T Pirttilä; S P Mehta; E A Sersen; P S Aisen; H M Wisniewski
Journal:  Arch Neurol       Date:  2000-01

2.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.

Authors:  E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust
Journal:  Brain       Date:  2008-11-28       Impact factor: 13.501

3.  Isn't amyloid more than just a marker for Alzheimer disease?

Authors:  Ronald J Killiany
Journal:  Neurology       Date:  2009-09-09       Impact factor: 9.910

4.  Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.

Authors:  Imrich Blasko; Kurt Jellinger; Georg Kemmler; Wolfgang Krampla; Susanne Jungwirth; Ildigo Wichart; Karl Heinz Tragl; Peter Fischer
Journal:  Neurobiol Aging       Date:  2006-10-19       Impact factor: 4.673

5.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

Authors:  Marieke van Oijen; Albert Hofman; Holly D Soares; Peter J Koudstaal; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-08       Impact factor: 44.182

6.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

7.  Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study.

Authors:  J-C Lambert; S Schraen-Maschke; F Richard; N Fievet; O Rouaud; C Berr; J-F Dartigues; C Tzourio; A Alpérovitch; L Buée; P Amouyel
Journal:  Neurology       Date:  2009-09-15       Impact factor: 9.910

8.  Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease.

Authors:  Nicole Schupf; Ming X Tang; Hide Fukuyama; Jennifer Manly; Howard Andrews; Pankaj Mehta; Jeffery Ravetch; Richard Mayeux
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

9.  Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.

Authors:  Johan Sundelöf; Vilmantas Giedraitis; Michael C Irizarry; Johan Sundström; Erik Ingelsson; Elina Rönnemaa; Johan Arnlöv; Malin Degerman Gunnarsson; Bradley T Hyman; Hans Basun; Martin Ingelsson; Lars Lannfelt; Lena Kilander
Journal:  Arch Neurol       Date:  2008-02

10.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Authors:  Clifford R Jack; Val J Lowe; Stephen D Weigand; Heather J Wiste; Matthew L Senjem; David S Knopman; Maria M Shiung; Jeffrey L Gunter; Bradley F Boeve; Bradley J Kemp; Michael Weiner; Ronald C Petersen
Journal:  Brain       Date:  2009-03-31       Impact factor: 13.501

View more
  39 in total

1.  Longitudinal Cognitive Profiles in Diabetes: Results From the National Alzheimer's Coordinating Center's Uniform Data.

Authors:  Mary Sano; Carolyn W Zhu; Hillel Grossman; Corbett Schimming
Journal:  J Am Geriatr Soc       Date:  2017-08-03       Impact factor: 5.562

2.  Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment.

Authors:  Jennifer L Bayer-Carter; Pattie S Green; Thomas J Montine; Brian VanFossen; Laura D Baker; G Stennis Watson; Laura M Bonner; Maureen Callaghan; James B Leverenz; Brooke K Walter; Elaine Tsai; Stephen R Plymate; Nadia Postupna; Charles W Wilkinson; Jing Zhang; Johanna Lampe; Steven E Kahn; Suzanne Craft
Journal:  Arch Neurol       Date:  2011-06

3.  Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI.

Authors:  Jon B Toledo; Hugo Vanderstichele; Michal Figurski; Paul S Aisen; Ronald C Petersen; Michael W Weiner; Clifford R Jack; William Jagust; Charles Decarli; Arthur W Toga; Estefanía Toledo; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Leslie M Shaw
Journal:  Acta Neuropathol       Date:  2011-07-30       Impact factor: 17.088

4.  Verbal serial list learning in mild cognitive impairment: a profile analysis of interference, forgetting, and errors.

Authors:  David J Libon; Mark W Bondi; Catherine C Price; Melissa Lamar; Joel Eppig; Denene M Wambach; Christine Nieves; Lisa Delano-Wood; Tania Giovannetti; Carol Lippa; Anahid Kabasakalian; Stephanie Cosentino; Rod Swenson; Dana L Penney
Journal:  J Int Neuropsychol Soc       Date:  2011-09       Impact factor: 2.892

Review 5.  Body fluid biomarkers in Alzheimer's disease.

Authors:  Huan Lu; Xi-Chen Zhu; Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-04

6.  Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City Study.

Authors:  Audrey Gabelle; Florence Richard; Laure-Anne Gutierrez; Susanna Schraen; Fleur Delva; Olivier Rouaud; Luc Buée; Jean-François Dartigues; Jacques Touchon; Jean-Charles Lambert; Claudine Berr
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.

Authors:  S C Burnham; N G Faux; W Wilson; S M Laws; D Ames; J Bedo; A I Bush; J D Doecke; K A Ellis; R Head; G Jones; H Kiiveri; R N Martins; A Rembach; C C Rowe; O Salvado; S L Macaulay; C L Masters; V L Villemagne
Journal:  Mol Psychiatry       Date:  2013-04-30       Impact factor: 15.992

8.  Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer's disease and vascular dementia.

Authors:  Sema Uslu; Zubeyde Eken Akarkarasu; Demet Ozbabalik; Serhat Ozkan; Omer Colak; Emine Sutken Demirkan; Ayşe Ozkiris; Canan Demirustu; Ozkan Alatas
Journal:  Neurochem Res       Date:  2012-03-22       Impact factor: 3.996

9.  Meta-analysis of plasma amyloid-β levels in Alzheimer's disease.

Authors:  Fei Song; Anne Poljak; Michael Valenzuela; Richard Mayeux; George A Smythe; Perminder S Sachdev
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

10.  MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice.

Authors:  Bin Liu; Jeffrey L Frost; Jing Sun; Hongjun Fu; Stephen Grimes; Peter Blackburn; Cynthia A Lemere
Journal:  J Neurosci       Date:  2013-04-17       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.